Elicio Therapeutics reports year-end 2024 results; press release text unreadable

Elicio Therapeutics, Inc.

2025-Q1 EPS reported -$0.87

Filing announces financial results for year ended Dec 31, 2024 and corporate updates.
Attached press release (Exhibit 99.1) contains extensive encoding corruption; specific figures not extractable.
No legible quantitative guidance or material non-financial updates identified in the exhibit.
Management change or other items not mentioned; only operational update alluded to.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.